Podcasts about MSI

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Ga maar even goed zitten voor het traditionele startschot van het weekend. Anderhalf uur aan gezellig, warm gekwebbel over videogames zal straks je trommelvliezen kietelen. Jelle, JJ en Koos zitten in de studio klaar. Ready om een nieuwe editie op te nemen van Einde van de Week Live. De talkshow waarin we elke week het belangrijkste game gerelateerde nieuws met jullie, de kijkers doornemen. En we hebben een prima line-up aan topics voor je klaarstaan. Zo discussiëren de drie over de acteurs die de rollen in de nieuwe Zelda film op zich gaan nemen. Hebben Nintendo en Miyamoto de juiste keuzes gemaakt. En hoe zit het met het gerucht dat er een nieuwe Animal Crossing game aankomt voor de Switch 2? Kan de reveal trailer van EA FC26 ons bekoren? Dit alles en meer ga je zien en horen in de Einde van de Week Live van vrijdag 18 juli 2025.Komt Animal Crossing al snel naar de Switch 2?Er is meer om over te praten. Wat gebeurt er als je de logo's van de games van Fron Software combineert met het artwork van Final Fantasy?Speel de bikkelharde soulslike Wuchang Fallen Feathets vanaf 24 juliFans van het soulslike genre (en dat zijn er veel hier) opgelet, er komt een nieuwe game aan waar jullie de tanden op kunnen stukbijten: Wuchang Fallen Feathers. Vanaf 24 juli kunnen jullie aan de slag met deze game die wordt gezien als een van de belangrijke releases van de zomer. Hier vind je alvast alle info over het spel.Scoor de Vector 16HX AI met 5080 aan boord voor scherpe prijsMSI zet deze week opnieuw een heavy duty gaming laptop in de spotlights. Het betreft de Vector 16 HX AI.  Onder de motorkap bevindt zich een Intel Core Ultra 9 275HX Processor, een NVIDIA GeForce RTX 5080 videokaart, een 1TB SSD, een 16” 240Hz QHD+ Scherm, een 24-zone RGB toetsenbord en Thunderbolt-5 aansluitingen voor al je randapparatuur. Deze krachtpatser is hier bij Azerty voor een scherpe prijs verkrijgbaar.Timestamps:Timestamps:00:00:00 Einde van de Week Live van 18 juli00:02:52 Donkey Kong Bananza00:08:10 Hoofdrolspelers van de Zelda film bekend gemaakt. 00:15:40 Huishoudelijke mededeling: MSI00:17:40 Nog meer Nintendo nieuws.00:22:33 EA FC 26 reveal trailer.00:25:23 From Software heeft nog een onaangekondigde game op stapel. 00:28:13 Assassin's Creed live-action serie. 00:31:18 BULLETTÎME: Wuchang Fallen Feathers00:37:45 Sucker Punch & Infamous. 00:41:31 Mortal Kombat 2 movie trailer.00:44:39 PlayStation store wordt overspoeld met AI gegenereerde games 00:50:02 Logo ontwerpen voor PlayStation.00:53:40 From Software meets Final Fantasy. 00:54:35 Cyberpunk 2077 komt met update 2.3.00:57:36 Leuke cijfers voor stat-freaks zoals JJ.00:59:08 PlayStation reclame in Japan. 01:00:03 Tekken voor senioren 01:02:32 ‘Jasper doet Tamriel' pt. 301:10:51 Cool of Serious Uncool?

Timestamps: 0:00 y'know how computers do stuff? 0:17 YouTube, Meta's slop crackdown 2:03 Grok govt contract, Companions 3:08 Steam game bans, Reddit age checks 4:29 MSI! 5:16 LTTStore LIME Day they made me sorry 5:55 QUICK BITS INTRO 6:01 Stream Xbox games you "own" 6:32 Google can call businesses for you 7:08 China AI chip restrictions lifted 7:43 Stellantis gives up on hydrogen 8:05 YouTuber Once Were Nerd facing jail NEWS SOURCES: https://lmg.gg/9u7vB Learn more about your ad choices. Visit megaphone.fm/adchoices

The boys discuss Patch 25.14, Tilt Brackets, MSI, emails and more on episode 699 of Leaguecast! Email us - mail@leaguecastpodcast.com   Support us - https://www.patreon.com/leaguecast  Tweet us - https://twitter.com/leaguecast   Facebook - https://www.facebook.com/Leaguecast/   Join Our Discord - https://discord.gg/leaguecast  Visit our Website - https://leaguecastpodcast.com/

From managing money in the treatment room to building long-term stability, financial literacy doesn't get enough attention in the beauty industry. In this episode of ASCP Esty Talk, Maggie and Ella get real about budgeting, pricing, and everything in between. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.    Website: https://tizoskin.com/  Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

Thorin and Yamato discuss the final matches of MSI 2025, the reasons why GenG are the best LoL esports team, T1 and Faker's performances at the event, what it will take for Western League of Legends teams to "bridge the gap" between them and Eastern teams, Maple un-retiring to return to PSG Talon, and more! Get the ultimate immersive gaming experience with Turtle Beach today! For a limited time only, head to https://TurtleBeach.com and use Code SUMMONING for 10% off your entire order. Upgrade your wallet today! Get 10% Off Ridge with code SI at https://www.Ridge.com/SI Control Body Odor ANYWHERE with Mando and get 20% off + free shipping with promo code SUMMONING at shopmando.com! Get up to 10 FREE meals and a free item for life at https://www.hellofresh.com/lfn10fm The Last Free Nation merch shop is open! Show off your fandom and support us and by purchasing  the high-quality items on our merch shop. Check our website for more info on shipping! https://go.lastfreenation.shop/summoningyt

IWDominate, Jamada, and dGon discuss GenG winning MSI 2025, the narratives surrounding Faker and runners-up T1, thoughts about Fearless Draft for Worlds and MSI, Dom's involvement with Cloud9, and more! ​Improve your game with a cutting-edge Wooting keyboard and get a free uWu now! Simply add any keyboard and uWu to your cart with code SPIKE and get your uWu for free! Go to https://link.wooting.io/powerspike Get 50% off FACTOR meals at https://www.factormeals.com/powerspike50off with code powerspike50off. High-quality, never-frozen meals delivered to your home! The Last Free Nation merch shop is open! Show off your fandom and support us and by purchasing  the high-quality items on our merch shop. Check our website for more info on shipping! https://go.lastfreenation.shop/powerspikeyt/

Geopolitical disruption in shipping has reached new heights in the first half of 2025 and Maritime Strategies International examine the impact on markets and what is the outlook ahead. The first half of the year has seen shipping markets impacted by President Trump's tariffs, the United States Trade Representative 301 investigation into Chinese shipbuilding, conflict in the Middle East, and ongoing sanctions and war in Ukraine.The Seatrade Maritime Podcast takes stock of movements in shipping markets over the first six months of 2025 and looks ahead at expectations for the remainder of the year.In this latest shipping markets outlook episode we are joined by analysts from Maritime Strategies International (MSI) to take a look at the outlook for containers, tankers, dry bulk, and shipbuilding in the second half of the year.Seatrade Maritime News Editor Marcus Hand discusses the outlook for shipping markets with Adam Kent, Daniel Richards, Will Fray, and Tim Smith from MSI.Setting the scene Adam says, “It's been yet another busy six months from a shipping market perspective, and I think there's even more moving parts now that we're having to grapple with, and these come on top of the ones that we have the start of the year.”Hear from the experts on their opinions about where different sectors are headed and learn about key trends impacting major sectors including:The impact of US President Trump's on/off tariffs on the container shipping marketWeak Chinese dry bulk demand and is China still the engine of growth for the sector?The impact of OPEC+ supply increases on demand in the tanker marketHow much do Korean and Japanese shipbuilders stand to gain from USTR fees on Chinese built and owned ships called US ports?Get ahead on the outlook for shipping in the second half of 2025 by listening to the full episode nowIf you enjoyed this episode, please subscribe to ensure you don't miss our latest uploads. For the latest news on the shipping and maritime industries, visit www.searade-maritime.com.Connect with Marcus Hand, Editor of Seatrade Maritime News:Follow on Twitter: https://twitter.com/marcushand1 Follow on LinkedIn: https://www.linkedin.com/in/marcus-hand-b00a317/Don't forget to join the conversation and let us know what topics you want us to cover in future on Twitter, Facebook or LinkedIn

Esportmaníacos 2328: En el programa de hoy hemos hablado de la final del MSI entre T1 y Gen G. Hemos pasado por encima por la final de losers en la que cayó Anyone's Legend y además hablamos de por qué desde Esportmaníacos no se hará cobertura de la Esports World Cup. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:21:05 - Esportmaníacos NO cubrirá la EWC 00:36:10 - Repaso rápido del T1 vs AL 00:47:30 - Revisamos LA FINAL DEL MSI 01:39:22 - ¿El mejor MSI de la historia?

Welcome back to a brand new episode of The Dive Driven by Kia. Chronicler joins Azael and Kobe right after the insanity of the MSI Finals! They discuss the future of Fearless within the competitive scene, cover FlyQuest's intense series against BilliBilli Gaming, and reflect on their experience at MSI. Thank you to the fans who showed up for an epic MSI in Vancouver, and for all the listeners who tuned into these episodes!With MSI now concluded, get ready as the LTA North returns July 26th with FlyQuest taking on Disguised at 1PM PT/4PM ET, followed by Cloud9 vs Lyon.Timestamps:0:00 Intro and T1 vs Gen.G Finals Recap 21:46 Doran was not the problem27:29 FlyQuest vs BiliBili Gaming42:52 MSI Memories & Fan Appreciation

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Het weekend komt er aan en daar zeggen we geen nee tegen. En waarom zouden we ook. Twee dagen niet werken en mogelijk lekker van de zon en de vrije tijd genieten, dat wil toch iedereen? We gaan dat weekend zoals altijd inluiden met een nieuwe aflevering van Einde van de Week Live. Om de overgang van werken naar rusten voor jou ietwat soepeler te laten verlopen. Klaar op de stoelzitten Jasper, JJ & Koos. Zij gaan hun licht laten schijnen over onder meer de State of Play over Ghost of Yotei, de hype rond Donkey Kong Bananza, de komst van S.T.A.L.K.E.R. 2: Heart of Chornobyl naar de PS5 en Bethesda dat aan meerdere Fallout-games werkt. Dit alles en veel, veel meer kun je zien en horen in de Einde van de Week Live van vrijdag 11 juli 2025.Brengt Ghost of Yotei meer van hetzelfde of zet Sucker Punch nieuwe stappen?Naast de bovenstaande onderwerpen praten de drie ook over de komst van Tony Hawk Pro Skater 3 + 4, de toekomst van Destiny 2, de Tokyo Game Show en er zijn wat nieuwe inzendingen voor Cool of Serious Uncool.Check de ‘nieuwe' Crosshairs 16 HX AI van MSI met een RTX 5070 aan boordNa al het geweld van de Upgrade Jouw Zomer actie, zet MSI dit keer de  ‘nieuwe' Crosshair 16 HX AI laptop in de spotlights. Aan boord bevinden zich een Intel Core Ultra 9 275HX Processor, een RTX 5070, een 1TB SSD, 32GB RAM, een 240HZ QHD panel, Thunderbolt4 en USB aansluitingen plus een RGB toetsenbord. Info over deze laptop kun je hier vinden: https://msi.gm/S5C76688 .Scoor de LG CineBeam Q 4K beamer met een dikke kortingLG heeft een buitenkansje voor mensen die van fijne en handzame gear houden. Met de draagbare CineBeam Q 4K beamer kun je jouw films en series bekijken waar je maar wil. In knisperend strak beeld. De CineBeam Q bevat 8,3 megapixels en tovert een scherm tot 120 inch op je muur of plafond. En ja, je kunt er ook een console op aansluiten. Er geldt nu hier een aanbieding bij LG die je 100 euro korting + een 60 euro voucher voor Pathé geeft bij aanschaf: https://tinyurl.com/3acdee24 .Timestamps:00:00:00 Einde van de Week Live van 11 juli00:01:05 Noodweer in Japan.00:07:39 Huishoudelijke mededeling: MSI00:10:02 State of Play: Ghost of Yotei.00:22:30 S.T.A.L.K.E.R. 2: Heart of Chornobyl komt naar PS5.00:24:28 Tony Hawk Pro Skater 3 + 4 bevat tien tracks uit het origineel.
00:29:00 Bethesda werkt aan meerdere Fallout games.00:32:33 Donkey Kong Bananza was bedoeld voor de eerste Switch.00:38:03 Nintendo zegt vaarwel tegen Nintendo Switch Game Vouchers.00:39:38 Tokyo Game Show.00:42:15 BULLETTÎME: LG CineBeam 00:44:21 Meest populaire game voor rest van 2025 op basis van whislist en aandacht. 00:47:47 Activision trekt Call of Duty WWII vanwege hackers.00:51:49 Japans internet zet wereldrecord.00:55:32 Ook in Japan: Het huren van een oma. 00:57:44 Destiny 2 probeert ommekeer te bewerkstelligen. 00:59:03 Nintendo Switch 2 nietmachine wordt geveild.01:00:10 Hulkenberg eerste podium in zijn carriere.01:01:58 Huisnijverheid, gemaakt door Black Thunder.  01:02:44 ‘Jasper doet Tamriel' pt. 201:12:45 COOL OF SERIOUS UNCOOL?

Esportmaníacos 2327: En el programa de hoy hemos hecho un repaso de la recta final del MSI. Ya solo quedan tres equipos en pie, dos coreanos y el campeón chino. Repasamos la serie de Anyone's Legend contra Bilibili Gaming, hemos hablado de la serie que disputará AL contra T1 y finalmente hemos visto la reacción de Supa al Método Tabe de entrenamiento. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:05:00 - No os habéis ganado los minutos, os los voy a dar pero remad 00:11:50 - NAVI llega a Berlín 00:23:05 - Repasamos el BLG vs AL 00:51:43 - Lo que haremos en ESPM con la EWC 00:53:00 - Seguimos con el MSI 01:24:46 - Hoy juega T1 01:40:30 - Supa habla del horario chino

Esportmaniacos 2326: En el programa de hoy hemos hecho un repaso completo por la serie de Gen G vs T1 que decidió al primer finalista del MSI. Tocamos por encima qué es lo que esperamos ver en la serie china que tenemos hoy enfrentando a Anyone's Legend contra Bilibili Gaming y finalmente hemos traído información sobre la offseason de Fnatic dado que fueron rechazados por Wunder. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g

In this episode of ASCP Esty Talk, we're wading into the therapeutic, challenging, and sometimes controversial relationship between skin and water—specifically, ocean water, geothermal hot springs, and chlorinated swimming pools. From ancient folklore to modern esthetics practices, we're exploring how these natural (and not-so-natural) waters impact the skin, the body, and the emotional state, plus what estheticians can recommend before and after exposure. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.    Website: https://tizoskin.com/  Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

Esportmaníacos 2325: En el programa de hoy hemos hablado del encuentro entre coreanos que viviremos en el MSI, dado que Gen G y T1 se cruzaran en la final de winners, asegurando así a un equipo de la LCK en la Gran Final del Mid-Season Invitational. Por otro lado, hemos repasado la serie entre FlyQuest y BLG en la que el campeón de LTA Norte casi consigue eliminar al segundo seed de la LPL. También hemos visto que Movistar KOI Fenix, academia de KOI en Superliga Domino's, ha hecho scrims públicas al más puro estilo de Los Ratones. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:20:00 - Movistar KOI Fenix muestra sus scrims 00:31:00 - Previa del Gen G vs T1 01:01:45 - Viene Sh4rin (como cada miércoles) 01:12:00 - FlyQuest CASI consigue vencer a BLG 01:46:55 - Caliste habla de lo vagos que son los jugadores en Europa

The boys discuss the ADC role, League Trivia, MSI, and more on episode 698 of Leaguecast! Email us - mail@leaguecastpodcast.com   Support us - https://www.patreon.com/leaguecast  Tweet us - https://twitter.com/leaguecast   Facebook - https://www.facebook.com/Leaguecast/   Join Our Discord - https://discord.gg/leaguecast  Visit our Website - https://leaguecastpodcast.com/

Esportmaníacos 2324: En el programa de hoy hemos contado con Dagartt, ex psicólogo de KOI para hablar de las rutinas de entrenamiento que hacen en China y Corea. Y es que en una entrevista con Caedrel, Tabe (head coach de Anyone's Legend) expuso cuál es su horario de trabajo en un día normal de la LPL y esto ha sorprendido mucho a la comunidad. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:14:35 - Vemos la formula del pandismo con Dagartt 01:21:50 - Entra Fernando Cardenete 01:43:50 - Declaraciones de Supa 01:54:24 - Hablamos (un poco) del MSI

Take a look at NZXT! - https://nzxt.co/travis ( Use code: travis5 )Check out Enchanted Travel at enchantedtravel.com !Follow Travis on Twitch: http://twitch.tv/travisgaffordSupport: https://linktr.ee/tgisupport00:00:00 Intro 00:10:32 yami asks Jamada for some perspective on EU roster instability and lack of success00:38:15 Narfidy's take: FLY has to beat BLG to have a successful MSI01:00:30 NZXT break!01:03:05 rawnblade apologizes to Jamada about dismissing Fearless format concerns01:19:00 Enchanted Travel break!01:22:20 mihir's take: this MSI is the greatest international or one of01:38:20 Acklon's take: FLY is going to beat BLG in less than 5 games, CFO will beat AL in their bo5, and more01:50:49 Outro

Thorin and Yamato give thoughts and analysis on MSI 2025, preview the upcoming banger matchup between Faker and T1 vs Chovy and GenG, discuss CFO's strong performances and upset potential vs AL, assess FlyQuest's chances to get a win vs BLG, give reasoning as to why the LEC squads didn't perform as strongly at MSI this year, and more! Upgrade your wallet today! Get 10% Off Ridge with code SI at https://www.Ridge.com/SI Control Body Odor ANYWHERE with Mando and get 20% off + free shipping with promo code SUMMONING at shopmando.com! Go to https://www.buyraycon.com/lfn TODAY to get up to 15% off their best-selling Everyday Earbuds! Last Free Nation merchandise is here! To celebrate, we're giving away several items from our merch shop. To be eligible, all you need to do is head to the Last Free Nation Discord server and follow the instructions in the "merch giveaway" channel. Entries will close next Sunday (the 13th), winners will be announced next week. Thank you for supporting our network! Last Free Nation Discord server: https://discord.gg/zeWYq4JhEU Last Free Nation merch shop: https://lastfreenation.shop

IWDominate, Jamada, and dGon discuss LEC representatives G2 and MKOI getting knocked out of MSI, Faker and T1's strong performances so far in the event and their chances of defeating tournament favorites GenG, FlyQuest's potential for lasting longer in MSI, the Top Lane debate for CFO, and more! Go to https://www.buyraycon.com/powerspike TODAY to get to 15% off their best-selling Everyday Earbuds! Last Free Nation merchandise is here! To celebrate, we're giving away several items from our merch shop. To be eligible, all you need to do is head to the Last Free Nation Discord server and follow the instructions in the "merch giveaway" channel. Entries will close next Sunday (the 13th), winners will be announced next week. Thank you for supporting our network! Last Free Nation Discord server: https://discord.gg/zeWYq4JhEU Last Free Nation merch shop: https://lastfreenation.shop/

Esportmaníacos 2323: En el programa de hoy hemos analizado la caída de Europa en el MSI. Ninguno de los equipos europeos ha conseguido ganar una serie en el main event, convirtiendo así a la LEC en la primera liga en perder toda su representación en el segundo torneo internacional del año. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:15:30 - Repasamos el MSI de G2 00:42:50 - ¿Qué ha pasado con KOI? 01:21:30 - La LEC es región Top 5

Welcome back to a brand new episode of The Dive, Driven by Kia. MSI 2025 is already delivering some exciting games, and the crew is here to break it all down. They take a look at standout moments from every region, including an unforgettable showdown between NA and EU, an impressive showing from the LCP, and absolute bangers featuring LCK and LPL powerhouses. The team also looks ahead to Week 2's high stakes matchups, spicy storylines, and discusses which teams are heating up and which ones might be in trouble.Who's looking the strongest? Who needs to bounce back? Let us know what you think in the comments below!MSI continues July 7 at 5PM PT/8PM ET. Timestamps:0:00 - Intro & Farewell to Europe3:23 - Champion Win rates at MSI9:31 - FlyQuest vs G2 Esports Recap26:05 - Gen.G vs Anyone's Legend Recap30:37 - The Evolution of Champion Strategies44:00 - Movistar KOI vs CTBC Flying Oyster Recap46:46 - T1 vs BLG Recap1:08:59 - CTBC Flying Oyster's Impressive Showing 1:17:43 - CTBC Flying Oysters vs Anyone's Legend Preview1:29:57 - FlyQuest vs BiliBili Gaming Preview1:37:42 - Gen.G vs T1 Preview

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.De vrije dagen van het welbekende weekend komen er aan en daar zijn we aan toe. Niet omdat werken zo zwaar is, maar vooral omdat de hitte ons wel redelijk parten speelden de afgelopen week. Gelukkig is het nu wat koeler en kunnen we normaal werken en genieten van het weer. Vanuit onze studio presenteren wij zoals elke week een verse aflevering van Einde van de Week Live. Om de overgang van werken naar rusten voor jou ietwat soepeler te laten verlopen. En het gaat er wel eentje worden ook. Want wat gebeurde er veel deze week en wat hadden we een aantal extra leuke onderdeeltjes klaar staan. In de studio zitten Huey, JJ & Koos klaar om hun licht te laten schijnen over de chaos bij Xbox en EA (Battlefield 6), de komst van Helldivers 2 naar Xbox en de plannen voor een nieuwe Ghost Recon game. Dit alles en veel, veel meer kun je zien en horen in de Einde van de Week Live van vrijdag 4 juli 2025.Chaos bij Xbox en de ontwikkeling van Battlefield 6Naast het rumoer rond Xbox en Battlefield 6 bespreken de drie ook leukere onderwerpen zoals de verkeerde relaunch van MindsEye, Donkey Kong Bananza, de drie games waar Insomniac aan werkt en de goede sales van Capcom, die echter niet voor de PS5 geldt. Tot slot is daar de première van het eerste deel van een vierdelige serie over Elder Scrolls Online die we zelf hebben gemaakt. Wij wilden wel eens zien of ESO een goede substituut is voor een dure zomervakantie. Info over ESO kun je hier vinden.Profiteer van fijne kortingen op bijvoorbeeld de MSI Katana A15 en maak kans op 250 cadeaukaart bij de ‘Upgrade Jouw Zomer' actieDe ‘E3'-periode is een speciale tijd. Een waar zomers spektakel voor gamers. En dus dachten MSI en Bol, hoe kunnen we deze mensen extra blij maken? De uitkomst is de ‘Upgrade Jouw Zomer actie'. Wat houdt de actie in? Heel simpel. Bij de aankoop van een MSI laptop met een RTX 4070 videokaart (bijvoorbeeld de Katana A15) of hoger aan boord (en ja, de 50-serie hoort daar ook bij), pak jij fijne kortingen EN je maakt kans op een zomerse Bol.com cadeaukaart ter waarde van 250 euro. Kun je mooi een nieuwe zwembroek, een koelbox of parasol kopen. De actie is hier te vinden. Have fun.Check de nieuwe Ruya Pro Gaming Chairs van GXTrustDe film Superman wordt naar verwachting de grote klapper deze zomer in de bioscopen. Ter ere van deze film brengt GXTrust een nieuw, officieel gelicenceerde DC Superman gaming chair uit (plus enkele ander producten). We hebben het over de Ruya Pro, een stoel met ingebouwde lendensteun, optimale hoogteverstelling, 4D-armleuningen en een kantelvergrendelingsmechanisme. Met of zonder Superman design te verkrijgen. Mocht je het liever wat zakelijker willen houden, maar toch willen gamen, dan zou je eens kunnen kijken naar de Ruya Fabric.Zet je muur in de spotlights met de Wall Washer van Philips HuePhilips Hue komt met een nieuw hebbedingetje: de (White & Color) Wall Washer. Een nieuw lamp, met een breed verlichtingsgebied en verrassend compact ontwerp zorgt voor de ultieme tv-verrijking. Dankzij de ColorCast-technologie en het slanke aluminium ontwerp kun je dit easy toevoegen aan je thuisbioscoop of gaming room. Interesse, check hier de pagina van de Wall Washer.   Timestamps:00:00:00 Intro00:04:02 MSI00:08:22 Xbox00:24:59 Phil Spencer00:31:32 Zenimax Shooter00:36:33 Helldivers 2 naar Xbox00:39:22 7e gen console games. 00:41:16 Donkey Kong Bananza00:45:23 Switch 2 verkopen00:45:32 BULLETTÎME: Trust00:49:28 Battlefield 600:54:03 CoD00:56:38 Ghost Recon 00:57:55 Insomniac werkt aan 3 games01:01:11 Jasper Doet Tamriel01:11:30 Anthem01:12:22 Stopkillinggames01:15:10 BULLETTÎME: Philips Hue01:18:10 Japanse vrouwen in games 01:19:52 MindsEye relaunch01:21:12 Trump over Disneyland01:24:30 Death Stranding 2

Esportmaníacos 2322: En el programa de hoy hemos traído a Koldo como invitado especial para analizar a fondo las series de BLG vs MKOI y de T1 vs CFO. Hemos pasado por los drafts y varias jugadas destacadas para intentar comprender cómo se dió el 3-1 de ayer favorable a KOI y posteriormente ver por qué T1 ha arrancado tan mal en este MSI. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:12:00 - Repasamos el KOI vs BLG 01:29:00 - Repasamos el T1 vs Ostras 01:47:00 - Previa del MSI

Esportmaníacos 2321: En el programa de hoy os hemos traído rumores e información sobre Fnatic exclusiva respecto al futuro del equipo. Después hemos hablado con DarthYellow de lo ocurrido con Thayger en LEC, dado que Rilech entrará en su puesto para 2026. Finalmente hemos hablado de Movistar KOI, equipo que juega hoy contra Bilibili Gaming en el MSI. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro con anuncio (mañana viene Koldo) 00:10:15 - Rumorcillo sobre Fnatic 00:32:02 - ¡Nos visita Darthyellow! 01:01:55 - Thayger ya tiene sustituto en NAVI 01:40:00 - Repaso del MSI

Thorin and Yamato discuss the results of the MSI 2025 Play-Ins, Poby leaving T1 for Fnatic, preview the MSI matches between GenG and G2, MKOI and BLG, AL and FlyQuest, plus CFO and T1, make predictions for the rest of the event, and more! Control Body Odor ANYWHERE with Mando and get 20% off + free shipping with promo code SUMMONING at shopmando.com! Shop the Into the AM Fourth of July Day Sale with up to 60% OFF until July 7! Save an additional 10% by using our link: https://intotheam.com/LFN Get up to 10 FREE meals and a free item for life at https://www.hellofresh.com/lfn10fm Go to https://www.buyraycon.com/lfn TODAY to get up to 15% off their best-selling Everyday Earbuds! The Last Free Nation merch shop is open! Show off your fandom and support us and by purchasing  the high-quality items on our merch shop. Check our website for more info on shipping! https://lastfreenation.shop

Esportmaníacos 2320: En el programa de hoy hemos hecho un repaso exhaustivo a la serie que tuvimos ayer entre G2 Esports y Gen G. Hemos contado con Teshrak, MFreak y Kharasu para analizar a fondo los drafts, planteamientos y jugadas clave del primer mejor de cinco de la fase principal del MSI. Además, hemos tenido a Sharin de invitado para charlar sobre su nuevo proyecto con AlexElCapo y hemos tocado ciertos rumores de LEC como la posibilidad de llevar a Razork al banquillo en Fnatic o Rhuckz subiendo a la LEC como assistant coach de Giantx. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro con poster de Supa 00:16:20 - Rhuckz sube a la LEC 00:29:00 - Repaso del Gen G vs G2 01:21:00 - Viene Sharin 01:35:40 - Rumores locos en Fnatic 01:57:50 - Mini previa del MSI

The boys discuss LoL Stats, TFT, Fun ‘Umm Actually League Games', MSI, and more on episode 697 of Leaguecast! Email us - mail@leaguecastpodcast.com   Support us - https://www.patreon.com/leaguecast  Tweet us - https://twitter.com/leaguecast   Facebook - https://www.facebook.com/Leaguecast/   Join Our Discord - https://discord.gg/leaguecast  Visit our Website - https://leaguecastpodcast.com/  

Take a look at NZXT! - https://nzxt.co/travis ( Use code: travis5 )Check out Enchanted Travel: https://enchantedhoneymoons.comFollow Travis on Twitch: http://twitch.tv/travisgaffordSupport: https://linktr.ee/tgisupport00:00:00 Intro 00:15:52 whale's take: AL are frauds00:31:10 Acklon's take: Sports betting coming into Esports was a forgone conclusion and it is not as bad as people are making it out to be0:46:00 NZXT break!00:49:10 Damastalex's take: C9 is going to come out of MSI a much better team than any of the western teams01:01:20 Jamada joins HLL!01:07:13 yami's take: LTA should get EU's second seed spot01:25:40 Able's take: With how fast paced the tournament has been, I'm not super aware of the storylines of the tournament right now01:41:08 Enchanted Travel break!01:44:52 basil's take: FLY can and should reach finals02:04:40 Rob's take: with the support meta being so engage dominated, the biggest game 5 decider in fearless Bo5's will be which teams/players will be able to find niche engage options or successfully play enchanters.02:15:00 Outro

IWDominate, Jamada, and dGon discuss G2's narrow victories in the MSI Play-ins , Mid Laner leaving T1 for Fnatic, predictions for all the upcoming matches at the MSI, thoughts on GAM and FURIA, and more! Shop the Into the AM Fourth of July Day Sale with up to 60% OFF until July 7! Save an additional 10% by using our link: https://intotheam.com/LFN Go to https://www.buyraycon.com/powerspike TODAY to get to 15% off their best-selling Everyday Earbuds!

Welcome back to The Dive Driven by Kia! Hot off the intense last day of MSI Play-Ins, Azael, Kobe, & Meteos break down all the action from the first 3 days and share how their MSI experience has been so far. With the Bracket Stage just around the corner, the crew look ahead at the exciting matchups, key players, and storylines to keep an eye on.The MSI Bracket Stage begins July 1st at 5:00pm PT/8:00pm ET as Gen.G takes on G2 Esports.Timestamps:0:00 - Intro & Initial Play-Ins Thoughts3:25 - FURIA MSI Performance8:30 - GAM vs G228:10 - BiliBili Gaming Domination32:06 - Bracket Stage Matchup Previews - G2 vs Gen.G 37:47 - FlyQuest vs Anyone's Legend45:59 - Movistar KOI vs BiliBili Gaming52:00 - CTBC Flying Oysters vs T1

Esportmaníacos 2318: En el programa de hoy hemos hecho un repaso exhaustivo al play-in del Mid-Season Invitational del que han clasificado G2 Esports y Bilibili Gaming para el main stage donde se encontrarán con Gen G y Movistar KOI respectivamente. También hemos repasado el mercato y hemos tocado especialmente el futuro de Fnatic dado que la organización ha hecho un cambio clave en su mid lane. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:16:03 - Barça Esports ficha a 113 00:18:50 - Ya conocemos el roster completo de NAVI 00:25:45 - Poby será el mid laner de Fnatic 01:03:50 - Repaso rápido de Furia y GAM 01:13:00 - Habrá rebranding en BDS 01:15:45 - ¿Ha vuelto el mejor BLG? 01:32:25 - G2 sufre en el play-in 01:52:40 - Vemos los horarios del MSI

Esportmaníacos 2316: En el programa de hoy hemos hecho previa del segundo torneo internacional del año, el Mid Season Invitational. Y es que hoy arranca este torneo y hemos aprovechado para hacer nuestra TIERLIST DE EQUIPOS DEL MSI. También hemos mirado por encima la actualidad del mercado ya que otro jugador español subirá a la LEC, siendo esta vez Thayger quién parece que jugará en las filas de NAVI. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:17:18 - Riot permite patrocinios de apuestas 00:36:55 - Thayger sube a LEC 00:53:50 - ¡Hoy empieza el MSI! 01:26:00 - Tierlist de equipos del MSI 01:50:55 - Los Más Buffados de Cacaolat

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.De twee vrije dagen komen er aan en het wordt tijd ook. Na een week hard werken is altijd heerlijk relaxen. Hopelijk ook in de zon. Vanuit onze studio presenteren wij een nieuwe editie van Einde van de Week Live. Om de overgang van werken naar rusten voor jou ietwat soepeler te laten verlopen. In de studio zitten Jasper, Jelle en Koos en ze gaan praten over een groot aantal onderwerpen. Bijvoorbeeld over hun indruk van de nieuwe beelden van de twee games die Capcom tijdens de Spotlight lieten zien, te weten Resident Evil Requiem en Pragmata. Ook waren er vermeende lekjes rondom GTA 6 Online, de launchdag van Death Stranding 2: On the Beach en een remaster van Little Big Planet. Dit alles en meer gaat aan je voorbij flitsen in de Einde van de Week Live van vrijdag 27 juni 2025.Wat vinden we van de eerste uren in Death Stranding 2: On the Beach?Andere onderwerpen betreffen de revival van turn based gameplay, de aanwezigen uitgevers op de Gamescom, de integratie van Steam in de Xbox PC app en de deal tussen Sonic the Hedgehog en McLaren.Profiteer van fijne kortingen op bijvoorbeeld de MSI Katana A15 en maak kans op 250 cadeaukaart bij de ‘Upgrade Jouw Zomer' actieDe ‘E3'-periode is een speciale tijd. Een waar zomers spektakel voor gamers. En dus dachten MSI en Bol, hoe kunnen we deze mensen extra blij maken? De uitkomst is de ‘Upgrade Jouw Zomer actie'. Wat houdt de actie in? Heel simpel. Bij de aankoop van een MSI laptop met een RTX 4070 videokaart (bijvoorbeeld de Katana A15) of hoger aan boord (en ja, de 50-serie hoort daar ook bij), pak jij fijne kortingen EN je maakt kans op een zomerse Bol.com cadeaukaart ter waarde van 250 euro. Kun je mooi een nieuwe zwembroek, een koelbox of parasol kopen. De actie is hier te vinden. Have fun.Timestamps: 00:00:00 Intro00:00:31 Huishoudelijke mededeling: MSI00:07:39 DEATH STRANDING 2 ON THE BEACH00:24:26 Capcom Spotlight stream met nieuwe beelden van Resident Evil Requiem en Pragmata.00:37:39 GTA 6 Online lekjes 00:40:44 Microsoft gaf ons de afgelopen week een blik in de toekomst. 00:45:52 Clair Obscur: Expedition 33 heeft turn based gameplay weer sexy gemaakt.00:49:29 Gamescom geruchtjes00:58:51 Update van Nintendo01:00:46 Iedereen wil een nieuwe Super Smash Bros voor de Switch 201:03:22 De schrijver van de The Witcher boeken bezig met nieuwe boeken01:07:28 Nieuwe beelden van Blood of the Dawnwalker.01:09:17 Was het vet geweest als dit er echt was gekomen01:11:39 Little Big Planet Remastered komt mogelijk naar PS5.01:12:52 Tweet van Koos gisteren.01:14:34 Sonic the Hedgehog maakt deal met McLaren01:17:09 Tim the Tatman: Game streamers are cooked.01:19:03 Cola Star Wars

Esportmaníacos 2315: En el programa de hoy hemos contado con Ibai Llanos y hemos charlado de los cambios internos en Movistar KOI, del MSI y de cómo ha sido llevar la fusión con MAD Lions y Movistar Riders. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos ¡Nuestro canal de VODs!: youtube.com/⁨@Esportmaniacosvods 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3

Thorin and Yamato preview MSI 2025! They are joined by guests Upset, Zaboutine, Initialise, Keire, and Vestion, who each bring their expertise and perspective on the LoL esports regions they follow. Keep tuning in to Last Free Nation during MSI for more Summoning Insight! Upgrade your wallet today! Get 10% Off Ridge with code SI at https://www.Ridge.com/SI Get the ultimate immersive gaming experience with Turtle Beach today! For a limited time only, head to https://TurtleBeach.com and use Code SUMMONING for 10% off your entire order. Control Body Odor ANYWHERE with Mando and get $5 off off your Starter Pack (that's over 40% off) with promo code SUMMONING at https://www.shopmando.com! Get 50% off FACTOR meals at https://www.factormeals.com/lfn50off with code lfn50off. High-quality, never-frozen meals delivered to your home! The Last Free Nation merch shop is open! Show off your fandom and support us and by purchasing  the high-quality items on our merch shop. Check our website for more info on shipping! https://lastfreenation.shop

The beauty industry often romanticizes the hustle mentality—work harder, work longer, always be on the go. But for many, this can have a real impact on personal relationships, mental health, and overall well-being. In this episode of ASCP Esty Talk, Maggie and Ella dive into the idea of work-life balance and redefine what success looks like in our industry. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   Skin Script Skin Care provides outstanding products and education, so estheticians prosper and succeed. Skin Script's three pillars are: amazing professional products, excellent customer service that is friendly and fast, and quality education at an approachable price. Skin Script delivers the promise of healthy, vitalized, youthful-looking skin by providing superior, innovative ingredients and formulations that are gentle yet effective. Skin Script Skin Care has been empowering estheticians since 2007 and welcomes you to unite with them in your professional journey.    YouTube: https://www.youtube.com/c/skinscriptrx   Facebook: https://www.facebook.com/skinscriptrx/   Instagram: https://www.instagram.com/skinscriptrx/?hl=en   Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

Esportmaniacos 2314: En el programa de hoy hemos contado con el head coach de Giantx, Andre Guilhoto para hacer una extensa previa del MSI y entender cómo vienen los diferentes equipos al segundo torneo internacional del año. Después contamos con Elyoya, jungla de Movistar KOI y le hemos entrevistado a pocos días de empezar la competición. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos ¡Nuestro canal de VODs!: youtube.com/⁨@Esportmaniacosvods 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:13:30 - ¿Gen G sufre contra los Pandas? 00:24:40 - Previa del MSI con Andre Guilhoto 01:24:00 - Viene ELYOYA

Welcome back to The Dive Driven by Kia! In this episode, Kobe and Meteos are joined by Emily Rand and Riot Cadmus, Modes Lead, to discuss all the changes coming to ARAM. Then, the crew breaks down Patch 25.13 (the MSI patch) and previews all the teams facing off in Vancouver.Timestamps:0:00 - Intro with Modes Lead Producer Riot Cadmus2:43 - ARAM Changes9:26 - ARAM Champion Buffs13:44 - Brawl, Arena, Swarm, Dominion & Twisted Treeline19:54 - ARAM All Time Teams25:10 - Exhaust in ARAM29:18 - MSI Meta Predictions & Patch 25.13 42:49 - Movistar KOI's Rise to 1st Seed  50:00 - BiliBili Gaming & Anyone's Legend1:01:49 - Gen. G & T11:08:11 - G2 Esports Expectations  1:09:50 - FURIA & GAM Esports 1:31:11 - CTBC Flying Oysters1:18:31 - FlyQuest 

The boys discuss Patch 25.13, Yunara, MSI, EWC, and more on episode 696 of Leaguecast! Email us - mail@leaguecastpodcast.com   Support us - https://www.patreon.com/leaguecast  Tweet us - https://twitter.com/leaguecast   Facebook - https://www.facebook.com/Leaguecast/   Join Our Discord - https://discord.gg/leaguecast  Visit our Website - https://leaguecastpodcast.com/ 

Dr. Shaalan Beg and Dr. Kristen Ciombor discuss practice-changing studies in GI cancers and other novel treatment approaches that were presented at the 2025 ASCO Annual Meeting. Transcript Dr. Shaalan Beg: Hello, I'm Dr. Shaalan Beg, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas, Texas. There were some remarkable advances in gastrointestinal cancers that were presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Kristen Ciombor to discuss some exciting GI data. Dr. Ciombor is the Ingram Associate Professor of Cancer Research and a co-leader of Translational Research and the Interventional Oncology Research Program at the Vanderbilt Ingram Cancer Center. Our full disclosures are available in the transcript of this episode. Dr. Ciombor, it's great to have you on the podcast today. Dr. Kristen Ciombor: Thanks, Dr Beg. It's great to be here. Dr. Shaalan Beg: Alright, let's kick it off. Big year for GI cancers. We'll start off with LBA1. This was the ATOMIC study sponsored by NCI and the National Clinical Trials Network (NCTN) and the Alliance group. This is a randomized study of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for stage III mismatch repair deficient colorectal cancer. Dr. Kristen Ciombor: I think this study was really definitely practice-changing, as you can tell because it was a Plenary. But I do have some concerns in terms of how we're actually going to implement this and whether this is the final answer in this disease subtype. So, as you said, the patients were enrolled with stage III resected mismatch repair deficient colon cancer, and then they were randomized to either modified FOLFOX6 with or without atezolizumab. And that's where it starts to become interesting because not many of us give FOLFOX for 6 months like was done in this study. Obviously, the study was done over many years, so that was part of that answer, but also the patients received atezolizumab for a total of 12 months. So the question, I think, that comes from this abstract is, is this practical and is this the final answer? I do think that this is practice-changing, and I will be talking to my patients with resected mismatch repair deficient colon cancer about FOLFOX plus atezolizumab. I think the big question is, do these patients need chemotherapy? And can we do a neoadjuvant approach instead? And that's where we don't have all the answers yet. Dr. Shaalan Beg: Yeah, but it has been great to see immunotherapy make its way into the adjuvant space after having made such a big impact in the metastatic space, but still some unanswered questions in terms of the need for chemotherapy and then the duration of therapy, which I guess we'll have to stay tuned in for the next couple of years to to get a lot of those questions answered. Dr. Kristen Ciombor: Yeah, but a big congratulations to the study team, to the NCTN, the NCI. I mean, this is really a great example of federally funded research that needs to continue. So, great job by the study team. The DFS 10% difference is really very large and certainly a practice-changing study. Dr. Shaalan Beg: Yeah, and and sticking with colon cancer, and and this another federally funded study, but this time funded by a Canadian cancer clinical trials group was LBA3510. This is the CHALLENGE study. It's a randomized phase 3 trial of the impact of a structured exercise program on disease-free survival for stage III or high-risk stage II colon cancer. This study got a lot of buzz, a lot of mainstream press coverage, and a lot of discussions on what that means for us for the patients who we're going to be seeing next week in our clinic. What was your takeaway? Dr. Kristen Ciombor: Yeah, this is a really interesting study, and I was so glad to see it presented because this partially answers one of the questions that patients always have for us in clinic, right? You know, once they've completed their standard chemotherapy and surgery, what else can they do to help prevent recurrence? And so we've always known and sort of extrapolated that healthy lifestyle habits are good, but now we have data, particularly in these patients. Most of them were stage III colon cancer patients, those had high-risk stage II cancer. And basically, the goal was to increase their physical activity by at least 10 MET hours per week. So, my big question, of course, as I came into this presentation was, “Okay, what does that mean exactly? How does that translate to real life?” And really what the author presented and explained was that basically most patients could hit their target by adding a 45- to 60-minute brisk walk 3 to 4 times a week. So I think this is very approachable.  Now, in the confines of the study, this was a structured exercise program, so it wasn't just patients doing this on their own. But I do think kind of extrapolating from that, that this is very achievable for most patients. And not only did this prevent recurrence of their prior cancer, but actually the rate of new primary cancer diagnoses, was less, which is really interesting, especially in the breast and prostate cancer. So this was a really interesting, and I think practice-changing study as well, especially given that this is something that most patients can do. Dr. Shaalan Beg: Yeah, and there was a lot of discussion in the hallways after the presentation in terms of how this really changes our existing practice because most folks already recommend exercise as a way for improving outcomes in cancer patients. So we've already been doing that. Now we have some data on how much it can impact the benefit. But there was some discussion about what the actual degree of impact was. There was a drop-off rate in terms of how long folks were able to stick with this exercise regimen. But you've seen this in clinic when someone have their surgery, they have their chemotherapy, they've been so intimately involved with the oncology world, with the oncology practice, and they somehow feel that they're being let loose into this mean, angry world without any guidance and they're looking for something to do. “What more can I do in terms of my lifestyle?” And then here we have very solid data, as solid as can be for an intervention like exercise, showing that there is an impact and you can give a prescription for exercise when someone wraps up their chemotherapy for colon cancer, thanks to the study. Dr. Kristen Ciombor: Yeah. It was a great study. Dr. Shaalan Beg: Moving to gastroesophageal cancer, another late-breaking abstract. This is LBA5. The MATTERHORN trial was a phase 3 trial of durvalumab plus FLOT for resectable GE junction and gastric cancer. And again, another area where immunotherapy has made an impact, and here we're seeing it move closer for earlier-stage disease. What was your take-home for the MATTERHORN trial? Dr. Kristen Ciombor: Yeah, so this study looked at neoadjuvant perioperative durvalumab plus our current standard chemotherapy of FLOT versus placebo plus FLOT. And this was a large study, almost 1,000 patients were randomized. And the primary endpoint was event-free survival, and it was definitely met in favor of the D + FLOT arm, as Dr. Klempner discussed after Dr Janjigian's presentation. I do think there are still some unanswered questions here. Overall survival is not yet mature, so we do have to wait and see how that shakes out. But it's very interesting and kind of is reflective of what, as you said, we're looking at earlier and earlier lines of therapy, particularly with immunotherapy, in these GI cancer spaces. So it makes a lot of sense to test this and and to look at this. So the toxicity was pretty similar to what we would expect. Primary endpoint was met, but again, we'll have to wait and see what the survival data looks like. Dr. Shaalan Beg: Yeah, and in oncology, we know, especially for treatment that does add additional cost, it does add additional potential toxicity that we want to see that overall survival nudged. I did see some polls on social media asking folks whether their practices changed from this, and I think the results were favoring adding durvalumab for this group of patients but understanding that there are caveats to the addition of treatments and the eventual FDA approval in that indication as well. Dr. Kristen Ciombor: Exactly. I completely agree with that. Dr. Shaalan Beg: All right. How about we stick with gastroesophageal cancer? LBA4002 was trastuzumab deruxtecan versus ramucirumab plus paclitaxel for second-line treatment in HER2-positive unresectable or metastatic gastric cancer or GE junction cancer. This was the DESTINY-Gastric04 study. And again, antibody-drug conjugates making a big impact across different diseases. And here we have more data in the HER2-positive gastric cancer space. Your thoughts on this study? Dr. Kristen Ciombor: Yeah, so this is a really important space in gastroesophageal cancer because the HER2 positivity rate is fairly high as compared to some of our other tumor types. So, I do think one of the important things was that patients did have biopsy confirmation of HER2 status, which was very important, and then they were randomized to either T-DXd versus the kind of second-line standard of ramucirumab-paclitaxel. So this was a great practical study and really answers a question that we had for a while in terms of does anti-HER2 therapy in the second-line really impact and improve survival. So we did see a statistically significant improvement favoring T-DXd. I do think it's always important to look at toxicity, though, too. And there was about almost 14% rate of interstitial lung disease, which of course is the most feared toxicity from some of these antibody-drug conjugates, especially T-DXd. So I do think it's important to keep that in mind, but this is definitely a great addition to the armamentarium for these HER2-positive patients. Dr. Shaalan Beg: And pancreas cancer was on the stage after a very long time with a positive clinical trial. This is Abstract 4006. These were preliminary results from a phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone for previously untreated metastatic pancreas cancer. This is a frontline clinical trial of gemcitabine/nab-paclitaxel plus/minus the study drug. There were other cohorts in this study as well, but they reported the results of their part 3B arm. And great to see some activity in the pancreas space. And your thoughts? Dr. Kristen Ciombor: Yeah, we definitely need better treatments in pancreas cancer. This was a very welcome presentation to see. The elraglusib is an inhibitor of GSK-3beta, and it's thought that that mediates drug resistance and EMT. And so this is, I think, a perfect setting to test this drug. So patients basically were randomized. Patients with metastatic pancreas cancer were randomized 2: 1 to gemcitabine/nab-paclitaxel plus or minus this elraglusib. So, what we saw was that overall survival was better with the addition of this new drug. And overall, not only the 1-year overall survival, but also median overall survival.  The thing that was interesting, though, was that we saw that the overall survival rates were 9.3 months with the combination versus 7.2 months with just gemcitabine/nab-paclitaxel. And that's a little bit lower than we've seen in other studies. So, not sure what was going on there. Was it the patients that were a bit sicker? Was it a patient selection, you know, thing? I'm not really sure how to explain that so much. Also, the toxicity profile was much higher in terms of visual impairment, with over 60% of patients being treated with the combination versus 9% with gemcitabine/nab-paclitaxel. So these were mild, grade 1 and 2, but still something to be cautious about. Dr. Shaalan Beg: And especially with this being a phase 2 trial, making sure that in a larger study we're able to better evaluate the toxicity and see if the control arm in the larger confirmatory study performs differently will be really important before this compound makes it to the clinic in our space. But very exciting to see these kinds of results for pancreas adenocarcinoma. Dr. Kristen Ciombor: Yeah. Dr. Shaalan Beg: We've talked, it seems, a couple of times on this podcast about the BREAKWATER clinical trial. We did hear PFS and updated OS data, updated overall survival data on first-line encorafenib plus cetuximab plus modified FOLFOX6 for BRAF-mutated colorectal cancer. This was LBA3500. And eagerly anticipated results – we have all previously heard the progression-free survival results – but here we heard updated overall survival results, and very well-received study it seemed from the audience that time. So what are your takeaways on the updated results for BREAKWATER? Dr. Kristen Ciombor: In my opinion, this was one of the most practice-confirming studies. As you mentioned, we've already seen some of the preliminary data of BREAKWATER at prior meetings. But really what was particularly impactful for me was the median overall survival with the BREAKWATER regimen. So, again, patients received FOLFOX, encorafenib cetuximab in the first line if they had BRAF-mutated V600E-mutated colorectal cancer. And the median PFS was 12.8 months, which was actually really remarkable in this traditionally very aggressive, poor prognosis subtype of tumors. So, by seeing a median overall survival of 30.3 months was just incredible, in my opinion. Just a few years ago, that was considered the median overall survival for all comers for metastatic colorectal cancer. And we know the median overall survival was more in the less than 12 months range for BRAF. So this was incredibly impactful, and I think should be absolutely practice-changing for anyone who is eligible for this regimen.  I think again, where the practice meets the study is what's kind of important to think about too, how long did patients get FOLFOX, and certainly it adds toxicity to add a BRAF-targeted regimen on top of FOLFOX already. So, one of the other interesting things about the study, though, was that even though it didn't complete treatment, they actually did look at encorafenib/cetuximab alone and in the first line without chemotherapy. And those preliminary results actually looked okay, especially for patients who might not be able to tolerate chemotherapy, which we certainly see in practice. So, overall, definitely more data. And I agree that it's certainly practice-changing. Dr. Shaalan Beg: And it completely, as you mentioned, changes the outlook for a person who's diagnosed with BRAF-mutated metastatic colon cancer today versus even 7 or 8 years ago. Dr. Kristen Ciombor: And we're seeing this over and over in other subtypes too, but how you choose to treat the patient up front really matters. So really giving the right regimen up front is the key here. Dr. Shaalan Beg: And along the same lines, Abstract 3501 wanted to answer the question on whether people with MSI-high metastatic colorectal cancer need double checkpoint inhibitor therapy or is single therapy enough. So this [CheckMate-8HW] study compared nivo plus ipi with nivo alone, nivo monotherapy for MSI-high metastatic colorectal cancer. And we've known that both of these are fairly active regimens, but we also know the chance of immune-related adverse events is significantly higher with combination therapy. So this was a much-needed study for this group of patients. And what were your takeaways here? Dr. Kristen Ciombor: This, of course, has been really nivo-ipi in the first-line MSI-high metastatic colorectal cancer is now a standard of care. And not everybody is eligible for it, and there could be reasons, toxicity reasons, and other things too. But as we've been seeing for the last couple of years, immunotherapy clearly beats chemo in this space. And now looking at doublet versus single immunotherapy treatment in the first line, I think really nivo-ipi does beat out monotherapy. I will say, however, there is a caveat in that we still haven't seen the nivo-ipi versus nivo in the first line. So what has been presented thus far has been across all lines of therapy, and that does muddy the waters a little bit. So definitely looking forward and and we've asked this many times and based on the statistical plan and and what not, you know, we just haven't seen that data yet. But I do think it's becoming increasingly important to consider doublet immunotherapy for these patients as long as there are no contraindications. With the again, with the caveat that we have to have these toxicity discussions in the clinic with patients because many patients can tolerate it, you know, this regimen fairly well, but there can be very severe toxicities. So, I think an informed discussion should really be had with each patient before moving forward. Dr. Shaalan Beg: Yeah, informed decision, making them aware of the potential of real significant toxicities, immune-related toxicities with double therapy. But I am curious in your practice, how often do you see people choosing doublet therapy as frontline? Dr. Kristen Ciombor: So patients are really savvy, and a lot of times they've heard this data before or have come across it in patient advocacy groups and other things, and it's really nice to be able to have that conversation of the risk versus benefit. So I will say not all of my patients choose doublet, and many of them are still cured with immunotherapy monotherapy. So the big question there is, will we ever understand who actually needs the doublet versus who can still be cured or have very good long-term outcomes with just the single agent? And that has not been answered yet. Dr. Shaalan Beg: What a great point. So the last abstract I was hoping we could talk about is POD1UM-303 or the INTERAACT2 subgroup analysis and impact of delayed retifanlimab treatment for patients with squamous cell carcinoma of the anal canal. What were your thoughts here? Dr. Kristen Ciombor: This was a study, actually we saw at ESMO, we saw the primary data at ESMO last year, and this was an update with some exploratory analyses. But this was really an important study because once again, we're looking at immunotherapy in later lines of therapy. That's how we started looking at and investigating immunotherapy, and now we're moving it up and up in the treatment course. So this was a study of carboplatin/paclitaxel plus or minus retifanlimab. Actually it was retifanlimab versus placebo. And it was a positive study, as we heard last year. This actually led to FDA approval of this regimen last month, just before ASCO, and it has now been incorporated in the NCCN guidelines as the preferred first-line option.  So what I thought was important from the additional data presented at ASCO was looking at the different subgroups, it did not appear that patients with liver mets or not had different outcomes. So that was really good to see because sometimes in colon cancer we see that immunotherapy doesn't work as well when patients have liver mets. And interestingly, because we use immunotherapy in anal cancer without any biomarkers, unlike with colon cancer or some of the other tumor types, also the authors looked at PD-L1 status, and it did look like maybe patients did a little bit better if they had higher PD-L1 expression, but patients still could benefit even if they were PD-L1 negative. So that was important, I think, and we will continue to see further data come out from this study. I want to mention also that EA2176 just completed accrual, so that was carbo-taxol plus or minus nivolumab. And so we should be seeing that data sometime soon, which will hopefully also confirm the ongoing role for immunotherapy in the first-line setting for anal cancer. Dr. Shaalan Beg: That was a fantastic review. Thank you, Dr Ciombor. Thanks for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Kristen Ciombor: Thanks for having me here. Dr. Shaalan Beg: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Shaalan Beg  @ShaalanBeg  Dr. Kristen Ciombor @KristenCiombor Follow ASCO on social media:    @ASCO on Twitter   @ASCO on BlueSky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Shaalan Beg:   Consulting or Advisory Role: Ipsen, Cancer Commons, Foundation Medicine, Science37, Nant Health, Lindus Health Speakers' Bureau: Sirtex Research Funding (Inst.): Delfi Diagnostics, Universal Diagnostics, Freenome Dr. Kristen Ciombor: Consulting or Advisory Role: Pfizer, Incyte, Exelixis, Bayer, ALX Oncology, Tempus, Agenus, Taiho Oncology, Merck, BeiGene Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calthera, Genentech, Seagen, Syndax Travel, Accommodations, Expenses: Incyte, Tempus

Esportmaníacos 2313: En el programa de hoy hemos tenido a Legolas de visita y con él hemos hablado de la posibilidad de que Thayger suba a LEC de mano de SK Gaming. Por otro lado, nos ha acompañado a hacer la tierlist de ADCs del MSI y finalmente hemos analizado a los Pandas y a Bilibili, los representantes de la LPL al Mid Season Invitational. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos ¡Nuestro canal de VODs!: youtube.com/⁨@Esportmaniacosvods 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:16:00 - Actualizaciones del mercato 00:22:40 - NAVI quería a Daglas 00:41:30 - ¿Thayger a LEC? 01:11:40 - Tierlist de ADCs del MSI 01:41:15 - Analizamos a los Pandas y a Bilibili

Esportmaníacos 2312: En el programa de hoy hemos cerrado finalmente todas las dudas del Caso Razork; tanto dónde puede ir como cuál será su futuro en el summer split de LEC. Después hemos hecho nuestra tierlist de mid laners del MSI, en la cuál hemos tenido varios debates paralelos. Más tarde, analizamos a Furia y sobre todo a T1 para ver cómo vienen al MSI y cuáles son sus principales rivales. Finalmente hemos contado con Legolas para hablar de la final del EMEA Masters, su desempeño dentro del Barça Esports y el motivo de la dominancia de Los Ratones de Caedrel en la competición de tier 2. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos ¡Nuestro canal de VODs!: youtube.com/⁨@Esportmaniacosvods⁩ 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:14:41 - Los costreamers del MSI 00:21:00 - Caso Razork 01:04:55 - Tierlist de mid laners del MSI 01:28:30 - Analizamos a FURIA y a T1 (sobre todo a T1) 01:48:00 - Hablamos con Legolas de la final del EMEA y Los Ratones

Send us a textWe dive into the major gaming announcements from PlayStation's State of Play and Xbox's Showcase events, comparing the different strategies each platform is taking and highlighting the most exciting upcoming games and hardware.• PlayStation VR is making a comeback with the upcoming game "Thief" featuring a new protagonist• Mortal Kombat Legacy Collection includes 20 games spanning multiple platforms for $69.99• Metal Gear Solid: Snake Eater remaster and Astro Bot DLC announcements generated significant excitement• PlayStation revealed their first official fight stick with wireless capabilities and mechanical switches• Xbox partnered with ASUS ROG and MSI to create Windows-powered gaming handhelds estimated to cost $600-800• Gears of War Reloaded and other Xbox games will come to PlayStation with physical releases while remaining digital-only on Xbox• Final Fantasy games are finally coming to Xbox but with disappointing early sales figures• Clockwork Revolution emerged as the standout game from the Xbox showcase• The "Megan 2" movie trailer shows a shift from horror to more sci-fi action• Gaming is increasingly incorporating political themes, raising questions about appropriate boundaries

In a new Summoning Insight, Thorin and Yamato discuss the banger LTA North Final between FlyQuest and Cloud9, Chovy taking GenG through another strong LCK split, whether AL can bring the LPL a win at MSI, and more! Get the ultimate immersive gaming experience with Turtle Beach today! For a limited time only, head to https://TurtleBeach.com and use Code SUMMONING for 10% off your entire order. ​Upgrade your wallet today! Get 10% Off Ridge with code SI at https://www.Ridge.com/SI Control Body Odor ANYWHERE with Mando and get $5 off off your Starter Pack (that's over 40% off) with promo code SUMMONING at https://www.shopmando.com! Go to https://www.buyraycon.com/lfn TODAY to get up to 15% off their best-selling Everyday Earbuds! 

In this episode of ASCP Esty Talk, Ella and Maggie dive into the wilder side of off-label skin care—the hacks your clients swear by (and you secretly hope they don't try). From using Monistat as makeup primer to dabbing toothpaste on zits and slathering on milk of magnesia to control shine, we unpack the surprising science, hidden risks, and when to gently intervene. Whether these creative shortcuts are rooted in desperation, TikTok trends, or passed-down “wisdom,” we're separating the myths from the mildly effective. Spoiler alert: Not all hacks belong in your routine, but some may spark a safer, pro-grade alternative. Read the Skin Deep article here ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   Skin Script Skin Care provides outstanding products and education, so estheticians prosper and succeed. Skin Script's three pillars are: amazing professional products, excellent customer service that is friendly and fast, and quality education at an approachable price. Skin Script delivers the promise of healthy, vitalized, youthful-looking skin by providing superior, innovative ingredients and formulations that are gentle yet effective. Skin Script Skin Care has been empowering estheticians since 2007 and welcomes you to unite with them in your professional journey.    YouTube: https://www.youtube.com/c/skinscriptrx   Facebook: https://www.facebook.com/skinscriptrx/   Instagram: https://www.instagram.com/skinscriptrx/?hl=en   Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

Aidan & Colton discuss Patch 25.12, Arena's return, Aram's update, MSI, and more on episode 695 of Leaguecast! Email us - mail@leaguecastpodcast.com   Support us - https://www.patreon.com/leaguecast  Tweet us - https://twitter.com/leaguecast   Facebook - https://www.facebook.com/Leaguecast/   Join Our Discord - https://discord.gg/leaguecast  Visit our Website - https://leaguecastpodcast.com/ 

Take a look at NZXT! - https://nzxt.co/travis ( Use code: travis5 )Check out Enchanted Travel at enchantedtravel.com !Follow Travis on Twitch: http://twitch.tv/travisgaffordSupport: https://linktr.ee/tgisupport00:00:00 Intro 00:14:14 Buttercup predicts FLY will have at minimum a semifinals appearance at MSI00:24:33 Tpepper's take: With recent performances at the last few worlds, LEC 2nd seed and LTA North 2nd seed should compete at MSI for the spot.00:39:42 mlewisno's take: part of why the LTA is exciting is because both C9 and FlyQuest have their villainous and heroic sides00:57:11 Frankalin asks Massu about his efforts in building his story and brand through content01:10:28 Enchanted Travel break!01:18:18 jarglyparf's take: Srtty being benched is the worst thing that DIG could've done01:32:12 kakashi's take: even though C9 lost to FLY, the narrative dominance of FLY is overblown01:44:40 Disappointment around MSI01:51:00 NZXT break! 01:53:10 ProfX's take: Near Airport leaving is a waste of the slot02:04:50 Outro

BUFFALO, NY - June 17, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence.” The study, led by first author Kavin Sugumar and corresponding author Jordan M. Winter, from University Hospitals Seidman Cancer Center, reports on a rare group of pancreatic cancer (PC) patients who responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type. The analysis, which includes data from 14 patients across multiple U.S. institutions, identifies outcomes that could help refine treatment strategies for one of the most aggressive and deadly forms of cancer. “Between 2020–21, 471 oncologists from 91 major cancer centers in the United States were contacted.” Pancreatic cancer has among the lowest survival rates and few effective therapies. While immunotherapy has transformed the treatment landscape for several other cancers, it generally offers little benefit for pancreatic cancer. However, this study highlights a small but important group of patients who experienced significant and sustained responses to immune-based treatment without chemotherapy. Most had advanced or metastatic disease and had already progressed after standard treatments. Among the 14 patients, 82% had partial tumor shrinkage, and nearly one-third had a notable decrease in tumor markers. The median progression-free survival was 12 months, and most patients were still alive at follow-up, with survival rates of 80% at one year and 70% at two years. These outcomes contrast sharply with standard therapies, which often provide only a few months of benefit for similar patients. Interestingly, while some patients had high microsatellite instability (MSI-high)—a known marker for immunotherapy success—more than half did not, suggesting other biological mechanisms may be involved. This result highlights the need for new biomarkers to be discovered to predict treatment response in future studies. This case series is the largest focused exclusively on exceptional immunotherapy responders in pancreatic cancer. By excluding patients who received chemotherapy, the study isolates the effects of immune-based drugs, including PD-1 inhibitors such as pembrolizumab and nivolumab, CTLA-4 inhibitors like ipilimumab, and agents targeting macrophages. While the sample size is small, the findings challenge the assumption that immunotherapy is ineffective for nearly all pancreatic cancer patients. The study suggests that, under certain biological conditions, this treatment can be remarkably successful. Further research is needed to understand the underlying mechanisms. This work supports the need to reconsider how clinical trials are designed for pancreatic cancer and who is eligible for immunotherapy. Broader criteria and more personalized molecular profiling could help uncover hidden opportunities for treatment in this highly lethal cancer. DOI - https://doi.org/10.18632/oncotarget.28739 Correspondence to - Jordan M. Winter - jordan.winter@UHHospitals.org Video short - https://www.youtube.com/watch?v=VeWTcuVmqgM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28739 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Welcome back to a spicy episode of The Dive Driven by Kia. The crew take on the bet payoffs they made earlier in the season featuring some extremely spicy peppers while recapping the LTA North Split 2 Conference Finals. After some time to cool off, we look ahead to MSI with the teams that have qualified, and talk region competitiveness and roster changes.Timestamps:0:00 Intro and the Spicy Pepper Bet5:20 C9 vs FLY Finals Recap 9:29 Zven Post Game Interview 12:35 C9 Nerves19:24 Game 323:04 Region competitiveness25:07 MSI & Scrims33:06 Roster Changes: Umti41:30 Other Roster Changes47:22 Back from break!47:25 MSI Attendees54:33 Outro

Is it actually safe to perform chemical peels during the summer months? In this episode of ASCP Esty Talk, Maggie and Ella tackle one of the hottest debated topics in esthetics, covering concerns like UV damage and post-inflammatory hyperpigmentation, offering tips on client selection and aftercare, and exploring safer summer alternatives. Tune in as they navigate the peel season—no matter the weather. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   Skin Script Skin Care provides outstanding products and education, so estheticians prosper and succeed. Skin Script's three pillars are: amazing professional products, excellent customer service that is friendly and fast, and quality education at an approachable price. Skin Script delivers the promise of healthy, vitalized, youthful-looking skin by providing superior, innovative ingredients and formulations that are gentle yet effective. Skin Script Skin Care has been empowering estheticians since 2007 and welcomes you to unite with them in your professional journey.    YouTube: https://www.youtube.com/c/skinscriptrx   Facebook: https://www.facebook.com/skinscriptrx/   Instagram: https://www.instagram.com/skinscriptrx/?hl=en   Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare